GlassScriptPhysician profile
Ronald D Kerwin
NPI 1265497622
$8,272.15
in general payments reported to CMS, 2019-2025
36 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $620 · 2021: $1,347 · 2022: $1,604 · 2023: $1,226 · 2024: $1,355 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,075 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $409 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,075.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $408.95 |
| Education | $264.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,361.82 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,332.74 | 2019-2025 | |
| Allergan, INC. | $928.10 | 2021-2022 | |
| Galderma Laboratories, L.P. | $794.42 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Sun Pharmaceutical Industries INC. | $669.92 | 2019-2025 | Winlevi |
| Dermavant Sciences, INC. | $427.84 | 2023-2024 | Vtama |
| Pfizer INC. | $364.83 | 2019-2025 | |
| Genzyme Corporation | $352.68 | 2019-2025 | |
| Ucb, INC. | $212.33 | 2019-2025 | Cimzia, Bimzelx |
| Leo Pharma INC. | $206.48 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $155.23 | 2019-2025 | Dupixent |
| Almirall LLC | $140.61 | 2019-2024 | Seysara |
| Novartis Pharmaceuticals Corporation | $138.26 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $101.84 | 2019-2024 | Jublia, Arazlo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $95.01 | 2021-2024 | Opzelura |
| Encore Dermatology INC. | $89.16 | 2019-2020 | |
| Lilly USA, LLC | $87.17 | 2022-2024 | Olumiant, Taltz, Ebglyss |
| Biofrontera INC. | $80.97 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $77.78 | 2025 | Sofdra |
| Amgen INC. | $71.73 | 2019-2024 | Otezla |
| Mayne Pharma Commercial LLC | $63.33 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.57 | 2023-2024 | Sotyktu |
| Organon LLC | $55.24 | 2023-2025 | Hadlima |
| Helsinn Therapeutics (U.S.), INC. | $44.12 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $42.47 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.92 | 2023 | Spevigo |
| Arcutis Biotherapeutics, INC. | $32.40 | 2023-2025 | Zoryve |
| Fresenius Kabi USA, LLC | $31.14 | 2023 | Idacio |
| Prugen, INC. Pharmaceuticals | $26.68 | 2019-2020 | |
| Kyowa Kirin, INC. | $21.41 | 2024 | Poteligeo |
| Journey Medical Corporation | $16.12 | 2025 | |
| Nabriva Therapeutics, Plc | $15.35 | 2021 | |
| Aclaris Therapeutics, INC. | $14.88 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.74 | 2023 | Ycanth |
| Sebela Pharmaceuticals INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Kerwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.